Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Still a Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares gapped up prior to trading on Monday . The stock had previously closed at $13.21, but opened at $13.7999. Astellas Pharma shares last traded at $13.28, with a volume of 845 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ALPMY shares. Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Astellas Pharma has a consensus rating of “Moderate Buy”.

Astellas Pharma Trading Up 2.6%

The stock has a fifty day moving average of $13.59 and a 200-day moving average of $14.65. The company has a market cap of $24.61 billion, a PE ratio of 12.66 and a beta of 0.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%. Sell-side analysts anticipate that Astellas Pharma Inc. will post 1.25 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).